Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMR), or Connected Persons, in compliance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding share awards rather than a financial performance report.
Material Changes
The filing details specific changes in share interests resulting from awards made under the GlaxoSmithKline 2009 Share Value Plan on August 25, 2015:
- Mrs V A Whyte (PDMR): Awarded 11,060 Ordinary Shares.
- Dr K Slaoui (Connected Person of Dr M Slaoui): Awarded 2,530 American Depositary Shares (ADS).
Market prices on the award date (August 25, 2015) were £12.96 per Ordinary Share and $39.41 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares awarded to PDMRs and Connected Persons under the 2009 Share Value Plan.
- Confirm the closing share prices used for valuation on August 25, 2015.
- Review the full 2009 Share Value Plan terms to understand vesting conditions associated with these awards.